Aloprim (Allopurinol) - Summary

ALOPRIM SUMMARY

ALOPRIM (allopurinol sodium) for Injection is the brand name for allopurinol, a xanthine oxidase inhibitor. ALOPRIM (allopurinol sodium) for Injection is a sterile solution for intravenous infusion only.

ALOPRIM (allopurinol sodium) for Injection is indicated for the management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.

ALOPRIM NEWS HIGHLIGHTS

Published Studies Related to Aloprim (Allopurinol)

A Double-Blind, Randomized, Placebo-Controlled 4-Week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole Adjunctive to Lithium in Acute Bipolar Mania. [2008.07.29]

Allopurinol to Prevent Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Randomized Placebo-Controlled Trial. [2008.02.25]

Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. [2007.04]

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. [2006.12.05]

Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. [2006.10]

more>>

Clinical Trials Related to Aloprim (Allopurinol)

Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil [Completed]

APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X [Recruiting]

Study of Rasburicase Versus Allopurinol in Patients With Leukemia, Lymphoma, or Solid Tumor Malignancy at Risk for Hyperuricemia and Tumor Lysis Syndrome [Active, not recruiting]

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. [Completed]

Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol [Recruiting]

more>>